Pharmacophore Modeling, 3D-QSAR Studies, and in-silico ADME Prediction of Pyrrolidine Derivatives as Neuraminidase Inhibitors

Chemical Biology and Drug Design

Volumn 79, Issue 3, 2012, Pages 353-359

  Zhang, Jie ^a   Pan, Xiaoyan ^a   Wang, Chen ^a   Wang, Fang ^a   Li, Pengfei ^a   Xu, Wenfang ^b   He, Langchong ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

ADME; Neuraminidase; Pharmacophore; Pyrrolidine; QSAR

Indexed keywords

PYRROLIDINE DERIVATIVE; SIALIDASE INHIBITOR;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG DESIGN; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; INFLUENZA; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ENZYME INHIBITORS; MODELS, MOLECULAR; NEURAMINIDASE; PYRROLIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE;

ORTHOMYXOVIRIDAE;

EID: 84862909453     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01299.x     Document Type: Article

References (28)

1. Pennisi E. (1995) Planning for the next flu pandemic. Science;270:1916-1917.
2. Liu C.G., Eichelberger M.C., Compans R.W. (1995) Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol;69:1099-1106.
3. Ghate A.A., Air G.M. (1998) Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design. Eur J Biochem;258:320-331.
4. Dao T.T., Nguyen P.H., Lee H.S., Kim E., Park J., Lim S.I., Oh W.K. (2010) Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. Bioorg Med Chem Lett;21:294-298.
5. Dobrovolny H.M., Gieschke R., Davies B.E., Jumbe N.L., Beauchemin C.A. (2011) Neuraminidase inhibitors for treatment of human and avian strain influenza: a comparative modeling study. J Theor Biol;269:234-244.
6. Oakley A.J., Barrett S., Peat T.S., Newman J., Streltsov V.A., Waddington L., Saito T., Tashiro M., McKimm-Breschkin J.L. (2010) Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem;53:6421-6431.
7. Wang G.T., Chen Y., Wang S., Gentles R., Sowin T., Kati W., Muchmore S., Giranda V., Stewart K., Kempf D., Laver W.G. (2001) Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. J Med Chem;44:1192-1201.
8. Abed Y., Nehmé B., Baz M., Boivin G. (2008) Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res;77:163-166.
9. Zhang J., Wang Q., Fang H., Xu W., Liu A., Du G. (2007) Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors. Bioorg Med Chem;15:2749-2758.
10. Ekins S., Williams A.J. (2010) Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development. Lab Chip;10:13-22.
11. Zhu H., Fang H., Cheng X., Wang Q., Zhang L., Feng J., Xu W. (2009) 3D-QSAR study of pyrrolidine derivatives as matrix metalloproteinase-2 inhibitors. Med Chem Res;18:683-701.
12. Qin J., Lei B., Xi L., Liu H., Yao X. (2010) Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis. Eur J Med Chem;45:2768-2776.
13. Tintori C., Magnani M., Schenone S., Botta M. (2009) Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors. Eur J Med Chem;44:990-1000.
14. Richmond N.J., Abrams C.A., Wolohan P.R., Abrahamian E., Willett P., Clark R.D. (2006) GALAHAD: 1. pharmacophore identification by hypermolecular alignment of ligands in 3D. J Comput Aided Mol Des;20:567-587.
15. Ryu C.K., Lee Y., Park S.G., You H.J., Lee R.Y., Lee S.Y., Choi S. (2008) 3D-QSAR studies of heterocyclic quinones with inhibitory activity on vascular smooth muscle cell proliferation using pharmacophore-based alignment. Bioorg Med Chem;16:9772-9779.
16. Clark R.D., Abrahamian E. (2009) Using a staged multi-objective optimization approach to find selective pharmacophore models. J Comput Aided Mol Des;23:765-771.
17. Weber K.C., Salum L.B., Honório K.M., Andricopulo A.D., da Silva A.B. (2010) Pharmacophore-based 3D QSAR studies on a series of high affinity 5-HT1A receptor ligands. Eur J Med Chem;45:1508-1514.
18. Zhang J., Wang Q., Fang H., Xu W., Liu A., Du G. (2008) Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors. Bioorg Med Chem;16:3839-3847.
19. Xiao J., Guo Z., Guo Y., Chu F., Sun P. (2006) Inhibitory mode of N-phenyl-4-pyrazolo[1, 5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses. Protein Eng Des Sel;19:47-54.
20. Crivori P., Poggesi I. (2006) Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur J Med Chem;41:795-808.
21. Falcó J.L., Lloveras M., Buira I., Teixidó J., Borrell J.I., Méndez E., Terencio J., Palomer A., Guglietta A. (2005) Design, synthesis and biological activity of acyl substituted 3-amino-5-methyl-1, 4, 5, 7-tetrahydropyrazolo[3, 4-b]pyridin-6-ones as potential hypnotic drugs. Eur J Med Chem;40:1179-1187.
22. Hu X.. (2006) In silico modeling of protein tyrosine phosphatase 1B inhibitors with cellular activity. Bioorg Med Chem Lett; 16: 6321-6327.
23. Long W., Liu P., Li Q., Xu Y., Gao J. (2008) 3D-QSAR Studies on a Class of IKK-2 Inhibitors with GALAHAD Used to Develop Molecular Alignment Models. QSAR Comb Sci;27:1113-1119.
24. Gueto C., Ruiz J.L., Torres J.E., Méndez J., Vivas-Reyes R. (2007) Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA. Bioorg Med Chem;16:2439-2447.
25. Chen Y., Li H., Tang W., Zhu C., Jiang Y., Zou J., Yu Q., You Q. (2008) 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem;44:2868-2876.
26. Sivan S.K., Manga V. (2010) Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J Mol Model;16:1169-1178.
27. Lu P., Wei X., Zhang R. (2010) CoMFA and CoMSIA studies on HIV-1 attachment inhibitors. Eur J Med Chem;45:1792-1798.
28. Gupta P., Roy N., Garg P. (2009) Docking-based 3D-QSAR study of HIV-1 integrase inhibitors. Eur J Med Chem;44:4276-4287.